Article
Medicine, General & Internal
Heather Wakelee, Moishe Liberman, Terufumi Kato, Masahiro Tsuboi, Se-Hoon Lee, Shugeng Gao, Ke-Neng Chen, Christophe Dooms, Margarita Majem, Ekkehard Eigendorff, Gaston L. Martinengo, Olivier Bylicki, Delvys Rodriguez-Abreu, Jamie E. E. Chaft, Silvia Novello, Jing Yang, Steven M. M. Keller, Ayman Samkari, Jonathan D. D. Spicer
Summary: Among patients with resectable early-stage NSCLC, perioperative pembrolizumab improved event-free survival, major pathological response, and pathological complete response. The addition of pembrolizumab to neoadjuvant chemotherapy followed by surgery showed significant benefits compared to neoadjuvant chemotherapy alone followed by surgery.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Ella A. Eklund, Clotilde Wiel, Henrik Fagman, Levent M. Akyurek, Sukanya Raghavan, Jan Nyman, Andreas Hallqvist, Volkan Sayin
Summary: This retrospective study investigated the impact of KRAS mutational status on clinical outcome in patients with metastatic non-small cell lung cancer (NSCLC). The results showed that KRAS(MUT) patients had better response to immune checkpoint blockade (ICB) but worse response to platinum doublet chemotherapy (PT). Additionally, KRAS(WT) patients with high PD-L1 expressing tumors responded better to PT than ICB.
Article
Oncology
Jane Yanagawa, Gregory J. Riely
Summary: Significant advances have been made in the treatment of resectable non-small cell lung cancer (NSCLC) and metastatic NSCLC, including the use of neoadjuvant nivolumab + chemotherapy and adjuvant atezolizumab, as well as molecular testing for various gene mutations and targeted therapies.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2022)
Review
Oncology
Stephanie P. L. Saw, Boon-Hean Ong, Kevin L. M. Chua, Angela Takano, Daniel S. W. Tan
Summary: Despite the advancements in treatment for advanced non-small-cell lung cancer (NSCLC), there is a renewed interest in neoadjuvant strategies for early-stage NSCLC. These strategies, including targeted therapy and immunotherapy, have the potential to greatly impact survival outcomes for early-stage NSCLC patients.
Article
Oncology
Fabrice Barlesi, Pascale Tomasini, Maryam Karimi, Stefan Michiels, Judith Raimbourg, Catherine Daniel, Henri Janicot, Anne Madroszyk, Clarisse Audigier-Valette, Elisabeth Quoix, Julien Mazieres, Denis Moro-Sibilot, Eric Dansin, Olivier Molinier, Hugues Morel, Eric Pichon, Alexis Cortot, Josiane Otto, Francois Chomy, Pierre-Jean Souquet, Nicolas Cloarec, Etienne Giroux-Leprieur, Ivan Bieche, Ludovic Lacroix, Sandrine Boyault, Valery Attignon, Isabelle Soubeyran, Alain Morel, Alicia Tran-Dien, Alexandra Jacquet, Filippo Gustavo Dall'Olio, Marta Jimenez, Jean-Charles Soria, Benjamin Besse
Summary: Targeted therapies and immune checkpoint blockers have revolutionized the treatment of non-small cell lung cancer. This study investigated the use of targeted therapies and immune checkpoint blockers as maintenance therapy based on molecular characterization. The results showed no significant differences in progression-free survival between targeted therapies and standard-of-care, and immune checkpoint blockers showed enhanced benefits in patients with PD-L1 >= 1%.
CLINICAL CANCER RESEARCH
(2022)
Review
Oncology
Jamie E. Chaft, Andreas Rimner, Walter Weder, Christopher G. Azzoli, Mark G. Kris, Tina Cascone
Summary: The treatment goal for early-stage lung cancer patients is cure, with surgical resection or radiotherapy as definitive local treatments along with adjuvant therapy to improve the likelihood of cure. New therapies lag behind due to inefficient trial designs and lengthy follow-ups, despite efforts to study surrogate endpoints to shorten trial durations.
NATURE REVIEWS CLINICAL ONCOLOGY
(2021)
Article
Medicine, General & Internal
John V. Heymach, David Harpole, Tetsuya Mitsudomi, Janis M. Taube, Gabriella Galffy, Maximilian Hochmair, Thomas Winder, Ruslan Zukov, Gabriel Garbaos, Shugeng Gao, Hiroaki Kuroda, Gyula Ostoros, Tho V. Tran, Jian You, Kang-Yun Lee, Lorenzo Antonuzzo, Zsolt Papai-Szekely, Hiroaki Akamatsu, Bivas Biswas, Alexander Spira, Jeffrey Crawford, Ha T. Le, Mike Aperghis, Gary J. Doherty, Helen Mann, Tamer M. Fouad, Martin Reck, AEGEAN Invest
Summary: In resectable non-small-cell lung cancer patients, perioperative durvalumab plus neoadjuvant chemotherapy showed significantly improved event-free survival and pathological complete response compared to neoadjuvant chemotherapy alone, with a similar safety profile.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Multidisciplinary Sciences
Sun Min Lim, Solange Peters, Ana Laura Ortega Granados, Gustavo dix Junqueira Pinto, Christian Sebastian Fuentes, Giuseppe Lo Russo, Michael Schenker, Jin Seok Ahn, Martin Reck, Zsolt Szijgyarto, Neda Huseinovic, Eleftherios Zografos, Elena Buss, Neda Stjepanovic, Sean ODonnell, Filippo de Marinis
Summary: This study compared the efficacy and safety of two different anti-PD-1 antibodies, dostarlimab and pembrolizumab, combined with chemotherapy as first-line treatment in patients with metastatic NSCLC. The results showed similar efficacy between the two antibodies, with dostarlimab performing better in the PD-L1-positive subgroup. Additionally, the DCT treatment group had a longer progression-free survival, but there was no significant difference in overall survival between the two groups.
NATURE COMMUNICATIONS
(2023)
Article
Medicine, General & Internal
Mariano Provencio, Ernest Nadal, Jose L. Gonzalez-Larriba, Alex Martinez-Marti, Reyes Bernabe, Joaquim Bosch-Barrera, Joaquin Casal-Rubio, Virginia Calvo, Amelia Insa, Santiago Ponce, Noemi Reguart, Javier de Castro, Joaquin Mosquera, Manuel Cobo, Andres Aguilar, Guillermo Lopez Vivanco, Carlos Camps, Rafael Lopez-Castro, Teresa Moran, Isidoro Barneto, Delvys Rodriguez-Abreu, Roberto Serna-Blasco, Raquel Benitez, Carlos Aguado de la Rosa, Ramon Palmero, Florentino Hernando-Trancho, Javier Martin-Lopez, Alberto Cruz-Bermudez, Bartomeu Massuti, Atocha Romero
Summary: This study evaluated the efficacy of the neoadjuvant nivolumab plus chemotherapy regimen on operable stage III non-small-cell lung cancer (NSCLC) patients. The results showed that patients receiving the combination therapy had a higher rate of pathological complete response and longer survival, indicating the effectiveness of this treatment approach in this patient population.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Oncology
Martin Reck, Jordi Remon, Matthew D. Hellmann
Summary: The past decade has seen significant progress in the treatment of metastatic non-small-cell lung cancer, with the development of specific antibodies leading to improved survival for many patients. Currently, nearly all mNSCLC patients receive PD-1 or PD-L1 therapy in the first-line setting, except those with targetable oncogenes.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Iktej Singh Jabbal, Saad Sabbagh, Mira Itani, Barbara Dominguez, Mohamed Mohanna, Valencia Henry, Hong Liang, Diana Saravia, Tiffany George, Zeina Nahleh, Evan Alley, Rafael Arteta-Bulos
Summary: Understanding the factors behind treatment refusal is crucial to improve cancer care and reduce disparities. This study analyzed data from the National Cancer Database and identified factors such as age, gender, income, insurance coverage, region, and comorbidity that were related to higher rates of chemotherapy refusal in patients with metastatic lung cancer. Retrospective studies exploring reasons for refusing standard treatment for NSCLC are lacking.
Article
Public, Environmental & Occupational Health
Xueyan Liang, Xiaoyu Chen, Huijuan Li, Xiaoxia Liu, Yan Li
Summary: This study evaluated the cost-effectiveness of the Chinese newly developed PD-L1 inhibitor sugemalimab plus chemotherapy (Sugema-Chemo) in China. The results showed that compared to chemotherapy alone, Sugema-Chemo increased QALY by 0.82 and life-years by 1.26, but with an average cost increase of $72,472. It was found that Sugema-Chemo might not be cost-effective for patients with metastatic NSCLC in China.
FRONTIERS IN PUBLIC HEALTH
(2023)
Review
Oncology
Qianqian Guo, Liwei Liu, Zelong Chen, Yannan Fan, Yang Zhou, Ziqiao Yuan, Wenzhou Zhang
Summary: Despite advancements in diagnosis and treatment, lung cancer mortality remains high. This review provides an overview of current diagnostic methods and therapies for non-small cell lung cancer, serving as a guide for clinicians.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, General & Internal
Bob T. Li, Egbert F. Smit, Yasushi Goto, Kazuhiko Nakagawa, Hibiki Udagawa, Julien Mazieres, Misako Nagasaka, Lyudmila Bazhenova, Andreas N. Saltos, Enriqueta Felip, Jose M. Pacheco, Maurice Perol, Luis Paz-Ares, Kapil Saxena, Ryota Shiga, Yingkai Cheng, Suddhasatta Acharyya, Patrik Vitazka, Javad Shahidi, David Planchard, Pasi A. Janne
Summary: Trastuzumab deruxtecan demonstrated durable anticancer activity in previously treated HER2-mutant NSCLC patients, with two cases of fatal drug-related interstitial lung disease reported. The observed toxic effects were generally consistent with previous studies.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Review
Pharmacology & Pharmacy
Zaid Sirhan, Rawan Alojair, Anita Thyagarajan, Ravi P. Sahu
Summary: Lung cancer is a major malignancy globally, with NSCLC being the most common type. PTEN, a tumor suppressor gene, plays a critical role in regulating cancer growth and its dysfunction is associated with poor prognosis in lung cancer patients. PTEN has been explored as a promising target for anti-cancer agents, as it can interact with multiple signaling pathways to devise effective treatment options for NSCLC.
Article
Oncology
Mitchell S. von Itzstein, Elda Railey, Mary L. Smith, Carol B. White, George W. Sledge, John R. Howell, Wendy Lawton, Donna M. Marinucci, Nisha Unni, David E. Gerber
Article
Oncology
Jin-Sung Chung, Vijay Ramani, Masato Kobayashi, Farjana Fattah, Vinita Popat, Song Zhang, Ponciano D. Cruz, David E. Gerber, Kiyoshi Ariizumi
CLINICAL CANCER RESEARCH
(2020)
Article
Oncology
David E. Gerber, D. Ross Camidge, Daniel Morgensztern, Jeremey Cetnar, Ronan J. Kelly, Suresh S. Ramalingam, David R. Spigel, Woondong Jeong, Pier P. Scaglioni, Song Zhang, Marilyn Li, David T. Weaver, Louis Vaikus, Mitchell Keegan, Joanna C. Horobin, Timothy F. Burns
Editorial Material
Oncology
Mitchell S. von Itzstein, David E. Gerber, John D. Minna
Summary: The study by Dagnino and colleagues identified CDCP1 as a potential biomarker for distinguishing patients with or without lung cancer, and demonstrated that combining CDCP1 blood levels with smoking history can be a predictive tool for lung cancer screening. Analysis of transcripts in peripheral blood cells suggested a Wnt/b-catenin signaling-based mechanism for CDCP1 in tumorigenesis, providing biological plausibility.
Article
Oncology
Sandi L. Pruitt, David E. Gerber, Hong Zhu, Daniel F. Heitjan, Bhumika Maddineni, Danyi Xiong, Amit G. Singal, Anna Tavakkoli, Ethan A. Halm, Caitlin C. Murphy
Summary: The study found that patients with previous cancer have worse overall survival but superior CRC-specific survival. Patients with previous melanoma had overall survival equivalent to those with no previous cancer. It is recommended that patients with previous melanoma and those with stage IV CRC with any type of previous cancer should be eligible to participate in clinical trials.
Editorial Material
Oncology
Erin L. Williams, Desiree L. Pierre, Mary E. Martin, Muhammad S. Beg, David E. Gerber
JCO ONCOLOGY PRACTICE
(2021)
Article
Oncology
David E. Gerber, Valerie L. Clark, Thomas Y. Sheffield, M. Shaalan Beg, Yang Xie, M. E. Blair Holbein, Celette Sugg Skinner, Simon J. Craddock Lee, Erin L. Williams
Summary: The COVID-19 pandemic has brought about significant changes in clinical research, such as remote consent, telehealth, and remote study monitoring. A survey conducted among cancer research professionals showed that perceptions of these adjustments remained favorable over time, and individuals with experience were more likely to recommend the continuation of these changes in the future.
JCO ONCOLOGY PRACTICE
(2022)
Article
Multidisciplinary Sciences
Ke Gong, Gao Guo, Nicole A. Beckley, Xiaoyao Yang, Yue Zhang, David E. Gerber, John D. Minna, Sandeep Burma, Dawen Zhao, Esra A. Akbay, Amyn A. Habib
Summary: The study explored the efficacy of broad versus focused targeting of resistance to EGFR inhibition in NSCLC, finding that a broad inhibitor of inflammation, prednisone, is the most effective in suppressing inflammatory signals and resistance mechanisms.
NATURE COMMUNICATIONS
(2021)
Letter
Oncology
Erin F. Williams, David E. Gerber
JCO ONCOLOGY PRACTICE
(2022)
Article
Oncology
Mitchell S. von Itzstein, Amrit S. Gonugunta, Thomas Sheffield, Jade Homsi, Jonathan E. Dowell, Andrew Y. Koh, Prithvi Raj, Farjana Fattah, Yiqing Wang, Vijay S. Basava, Shaheen Khan, Jason Y. Park, Vinita Popat, Jessica M. Saltarski, Yvonne Gloria-McCutchen, David Hsiehchen, Jared Ostmeyer, Yang Xie, Quan-Zhen Li, Edward K. Wakeland, David E. Gerber
Summary: Patients treated with antibiotics have worse outcomes from cancer immunotherapy, potentially due to the impact of antibiotics on the gut microbiome. This study found significant differences in immune parameters, including antibodies and cytokines, according to antibiotic exposure.
Editorial Material
Oncology
Christa Braun-Inglis, Erin L. Williams, Alyssa Macchiaroli, Andrea Denicoff, David E. Gerber
JCO ONCOLOGY PRACTICE
(2022)
Article
Oncology
Amrit S. Gonugunta, Mitchell S. Von Itzstein, David Hsiehchen, Tri Le, Sawsan Rashdan, Hui Yang, Christopher Selby, Carlos Alvarez, David E. Gerber
Summary: Antibiotic exposure is more common in lung cancer and melanoma patients, especially in lung cancer patients. These observations may have implications for clinical practice and health policies.
CLINICAL LUNG CANCER
(2022)
Editorial Material
Oncology
Sherry Fu, David E. E. Gerber, Muhammad Shaalan Beg
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Alexis C. Boulter, Barry J. Maurer, Meredith Pogue, Min H. Kang, Hwangeui Cho, Amanda Knight, C. Patrick Reynolds, Donald Quick, Sanjay Awasthi, David E. Gerber
Summary: This study is a clinical trial of the combination therapy of synthetic retinoid 4-HPR and a variant dihydroceramide precursor. The results show that this combination therapy has limited efficacy in refractory solid tumors.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2023)
Editorial Material
Oncology
David E. Gerber
JOURNAL OF CLINICAL ONCOLOGY
(2023)